We have a first in class treatment and a robust pipeline of potential new medicines for a variety of chronic inflammatory diseases. We currently have a marketed product with several indications in dermatology, respiratory and gastroenterology, and being evaluated for additional conditions, including ones with underlying type 2 inflammation. Another marketed product is currently indicated for rheumatological conditions, arthritis and polymyalgia rheumatica, and is also being evaluated for additional indications. Our robust pipeline in immunology has us exploring key areas in more than a dozen disease states.

Amit, Asthma, Israel

Did you know


Healthy type 2 immunity helps protect against parasites, while type 1 immunity helps defend against bacteria, viruses and other microorganisms. (1)


Type 2 inflammation can go into overdrive. Our flagship medicine is approved to treat five different diseases caused by this.


We’re running clinical trials of 13 different therapies for inflammatory conditions.

Elizabeth, atopic dermatitis, US
Elizabeth, atopic dermatitis, US

A pioneer in type 2 inflammation

In less than a decade, we changed the lives of many people with atopic dermatitis. Then we asked, "Can we take this science further?"

We did. We helped people living in fear of their next asthma attack, and those suffering from chronic rhinosinusitis with nasal polyposis. We’re still going, unlocking potential treatments for people with dermatologic, respiratory, and gastrointestinal diseases.

Jeff, asthma, Canada
Jeff, asthma, Canada

Restoring immune balance

We’re exploring immune disorders beyond type 2 inflammation using our precision immunology approach.

Our teams are helping rebalance the immune system using new technologies to tackle diseases like adult rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile arthritis.

Miwako, atopic dermatitis, Japan
Miwako, atopic dermatitis, Japan

What’s next in immunology?

Where will we go next? We'll push the science of immunology further and continue learning from our friends and neighbors who know their diseases better than anyone.

They’re counting on us. That’s why we will never settle.


  1. Gieseck RL 3rd, Wilson MS, Wynn TA (2018) Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol 18:62-76; DOI: 10.1038/nri.2017.90